Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GUTBUN-DS
- Development stage
- Unknown
- Lead developer
- Intra Life
- Modality
- Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
GUTBUN-DS is a high-potency probiotic supplement containing a blend of 90 billion colony-forming units (CFU) of live microbial strains. Marketed by Intra Life, a PCD pharmaceutical company in India, it is designed to support gastrointestinal health and provide supportive management for diarrhea. The mechanism of action involves the modulation of the intestinal microbiota, the enhancement of the intestinal mucosal barrier, and the restoration of microbial homeostasis. By introducing beneficial bacteria into the gut, GUTBUN-DS helps to suppress the overgrowth of pathogenic microorganisms and supports the local immune environment, thereby promoting overall gut health and recovery from diarrheal episodes.
- Brand names
- GUTBUN-DS
- Other names
- Probiotics (90B CFU blend)
Beyond the preview
Go deeper on GUTBUN-DS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GUTBUN-DS.